Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 8, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08

Reporting Person: O'Brien Stephanie Monaghan (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$14.00	2027-11-08	Common Stock (121894)		Direct

Footnotes

F1: This option was granted on November 8, 2017 and immediately vested as to 50% of the shares underlying the option on November 8, 2017, with the remainder vesting in 12 equal monthly installments with the first installment vesting on December 8, 2017.